On the one hand, it is probable that the use of galectin-3 to diagnose cardiovascular illness in cancer survivors in clinical practice may be impacted by the overlap between the pathophysiology of cardiovascular disease and cancer, including inflammation and cell proliferation [28]. The gene discussed is LGALS3; the disease is cancer.